RxDoctor Payments Data

Arman Janloo, MD

Family Medicine · Columbia, MDNPI 1710169446

Payments from drug & device makers

$1,253in general payments, 2019–2025

Across 72 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$289
  • Biohaven Pharmaceutical Holding Company Ltd.$137
  • Boehringer Ingelheim$96
  • Lilly USA, LLC$96
  • GSK$87
  • Biohaven Pharmaceuticals, Inc.$82
  • plus $466 from 15 others

What the payments were for

  • Food & beverage$1,253100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,253 in reported general payments places this provider in the 70th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$476,298
Medicare patients
285
Services billed
5,167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban596$175,138
JanuviaSitagliptin Phosphate121$33,963
JardianceEmpagliflozin104$30,113
TrulicityDulaglutide25$24,509
Cinacalcet Hcl26$21,447
Budesonide92$21,326
Incruse ElliptaUmeclidinium Bromide54$20,456
Quetiapine Fumarate627$16,800
OzempicSemaglutide16$16,390
Lagevrio (Eua)Molnupiravir14$13,972
Mirtazapine378$13,849
Atorvastatin Calcium644$11,713
ErtapenemErtapenem Sodium24$11,070
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$11,006
ArexvyRsvpref3 Antigen/As01e/Pf33$10,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$69$175,138596 claims
GSKIncruse Ellipta, Trelegy Ellipta, Arexvy, Anoro Ellipta, Shingrix$87$56,109182 claims
MerckJanuvia, Lagevrio (Eua)$25$47,935135 claims
Boehringer IngelheimJardiance$96$30,113104 claims
Lilly USA, LLCTrulicity$96$24,50925 claims
Novo NordiskOzempic$40$16,39016 claims
AbbVieLinzess$289$9,85717 claims
Johnson & JohnsonXarelto$17$8,48430 claims
Astellas Pharma US IncMyrbetriq$32$6,18527 claims
AstraZenecaBrilinta$18$5,63225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Columbia

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →